Differing results of trials of glucosamine for pain in arthritis: Comment on the article by Vlad et al [5]

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 332-333

  Moore, Andrew ^a   Derry, Sheena ^a   McQuay, Henry ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE;

DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; LETTER; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SAMPLING;

CLINICAL TRIALS AS TOPIC; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; PAIN;

EID: 38149111200     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23183     Document Type: Letter

References (11)

1. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007;56:2267-77.
2. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 2000;85:415-24.
3. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
4. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004; 51:738-45.
5. Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest [editorial]. Arthritis Rheum 2007;56:2105-10.
6. Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain 2006;121:207-18.
7. Hill AB. Principles of medical statistics. 9th ed. New York: Oxford University Press; 1971. p. 17.
8. Moore RA, McQuay HJ. Bandolier's little book of understanding medical evidence. Oxford and New York: Oxford University Press; 2006.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
10. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2002;2:14.
11. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-98.